KA Imaging’s Flat Panel Sight™ has received a Canadian Medical Device Licence from Health Canada. With the licence, the X-ray detector can be officially sold in Canada.
Biognosys announces today that it has established a strategic agreement with Siemens Healthineers through its clinical laboratory in Berkeley, California.
The first study of its kind reports on the enhancement of skin permeability of risperidone (RIS) using eutectic systems.
Porvair Sciences has launched new kits for rapid extraction of total RNA from a wide range of biological samples. These proprietary kits enable extraction of up to 1000 µg of application-ready pure RNA in as little as 10 minutes.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.
Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).
A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.
Recently, researchers from the U.S. reviewed electronic health records of SARS-CoV-2 patients at a medical center that started mAb infusions in January 2021 with the support of the National Disaster Medical System, part of the U.S. Department of Health and Human Services. The study is published on the preprint server, medRxiv.